Genix Pharmaceuticals Corporation (GENPF)
OTCMKTS
· Delayed Price · Currency is USD
0.0138
-0.0262 (-65.50%)
At close: Jun 6, 2025
Genix Pharmaceuticals Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 30, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | 2015 - 2019 |
| 0 | 0 | 0.01 | - | - | - | Upgrade
| |
Revenue Growth (YoY) | -81.17% | -67.19% | - | - | - | - | Upgrade
|
Cost of Revenue | 0.18 | 0.18 | 0.01 | - | 0 | - | Upgrade
|
Gross Profit | -0.18 | -0.18 | 0 | - | -0 | - | Upgrade
|
Selling, General & Admin | 0.14 | 0.15 | 0.23 | 0.18 | 0.26 | 0.22 | Upgrade
|
Operating Expenses | 0.16 | 0.18 | 0.84 | 1 | 1.61 | 0.68 | Upgrade
|
Operating Income | -0.35 | -0.36 | -0.83 | -1 | -1.61 | -0.68 | Upgrade
|
Interest Expense | -0.15 | -0.12 | -0.05 | -0.01 | -0 | -0 | Upgrade
|
Interest & Investment Income | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Currency Exchange Gain (Loss) | -0 | -0 | -0.01 | -0.03 | 0 | -0 | Upgrade
|
Other Non Operating Income (Expenses) | -0.06 | -0.06 | -0.05 | -0.03 | -0.05 | -0.04 | Upgrade
|
EBT Excluding Unusual Items | -0.56 | -0.55 | -0.94 | -1.07 | -1.65 | -0.72 | Upgrade
|
Asset Writedown | - | - | -3.46 | - | - | - | Upgrade
|
Other Unusual Items | 0.47 | 0.47 | - | - | - | - | Upgrade
|
Pretax Income | -0.09 | -0.07 | -4.4 | -1.07 | -1.65 | -0.72 | Upgrade
|
Earnings From Continuing Operations | -0.09 | -0.07 | -4.4 | -1.07 | -1.65 | -0.72 | Upgrade
|
Net Income | -0.09 | -0.07 | -4.4 | -1.07 | -1.65 | -0.72 | Upgrade
|
Net Income to Common | -0.09 | -0.07 | -4.4 | -1.07 | -1.65 | -0.72 | Upgrade
|
Shares Outstanding (Basic) | 59 | 59 | 59 | 59 | 59 | 50 | Upgrade
|
Shares Outstanding (Diluted) | 59 | 59 | 59 | 59 | 59 | 50 | Upgrade
|
Shares Change (YoY) | - | - | - | - | 18.55% | 33.17% | Upgrade
|
EPS (Basic) | -0.00 | -0.00 | -0.07 | -0.02 | -0.03 | -0.01 | Upgrade
|
EPS (Diluted) | -0.00 | -0.00 | -0.07 | -0.02 | -0.03 | -0.01 | Upgrade
|
Free Cash Flow | -0.16 | -0.19 | -0.22 | -0.22 | -0.43 | -0.2 | Upgrade
|
Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.00 | Upgrade
|
Gross Margin | - | - | 26.43% | - | - | - | Upgrade
|
Operating Margin | -32548.92% | -8986.67% | -6737.05% | - | - | - | Upgrade
|
Profit Margin | -8193.91% | -1806.86% | -35600.34% | - | - | - | Upgrade
|
Free Cash Flow Margin | -15334.68% | -4624.54% | -1787.27% | - | - | - | Upgrade
|
EBITDA | 0.2 | 0.18 | -0.29 | -0.46 | -1.09 | -0.32 | Upgrade
|
EBITDA Margin | 18649.58% | 4498.59% | - | - | - | - | Upgrade
|
D&A For EBITDA | 0.55 | 0.55 | 0.55 | 0.54 | 0.52 | 0.36 | Upgrade
|
EBIT | -0.35 | -0.36 | -0.83 | -1 | -1.61 | -0.68 | Upgrade
|
Revenue as Reported | 0 | 0 | 0.01 | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.